This site requires Flash 8.

If you are seeing this message it indicates that Flash has not been properly installed.

You can install Flash by visiting the Adobe website or clicking here.

Patients

Home >  Patients

From the many millions of people throughout the world suffering from infectious diseases to the immunocompromised patients at high risk of certain deadly viral threats, we at ViroPharma through our research are dedicated to finding new ways to improve the health of patients suffering from serious diseases.

Our clinical efforts are primarily focused in gastroenterology and in transplant medicine, anchored by our anti-cytomegalovirus drug, maribavir.

ViroPharma commercializes Vancocin, a life saving drug for patients suffering from severe Clostridium difficile infection (CDI). Our mission, as stewards of public health related to CDI, is to do all that we can - in every way that we can - by working with physicians toward enabling quick identification and appropriate treatment of patients who are most at risk of severe disease, and to keep other patients infection-free.

Learn more about our therapeutic areas, gastroenterology and hospital/transplant medicine

Cytomegalovirus (CMV)

Patients who are immunosuppressed following hematopoietic stem cell (SCT) or solid organ transplantation (SOT) remain at high risk of CMV infection. Learn More

Hepatitis C

The current standard of care for HCV patients is not an option for everyone, and only about 50 percent of treated patients are cured of the infection. Learn More

Clostridium difficile-Infection (CDI)

C. difficile infection has become one of the most common nosocomial (spread patient to patient in a hospital) infections. Learn More